Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 9 (September)

1. Macrophage inflammatory protein (MIP)1alpha and MIP1beta differentially regulate release of inflammatory cytokines and generation of tumoricidal monocytes in malignancy.
   Cancer Immunol Immunother, 55(12): 1534-41. [Abstract] [Full-text]
2. Wnt-5a mRNA translation is suppressed by the Elav-like protein HuR in human breast epithelial cells.
   Nucleic Acids Res, 34(14): 3988-99. [Abstract] [Full-text]
3. Stat5 in the mammary gland: controlling normal development and cancer.
   J Cell Physiol, 209(2): 305-13. [Abstract] [Full-text]
4. BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells.
   Exp Cell Res, 312(16): 3120-31. [Abstract] [Full-text]
5. Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferationin the breast.
   Genes Chromosomes Cancer, 45(11): 1007-17. [Abstract] [Full-text]
6. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.
   Genes Chromosomes Cancer, 45(11): 1033-40. [Abstract] [Full-text]
7. Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers.
   Genes Chromosomes Cancer, 45(11): 983-94. [Abstract] [Full-text]
8. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
   Cancer Chemother Pharmacol, 58(6): 742-8. [Abstract] [Full-text]
9. Panmucositis and chemosensitisation associated with betel quid chewing during dose-dense adjuvant breast cancer chemotherapy.
   Cancer Chemother Pharmacol, 58(6): 835-7. [Abstract] [Full-text]
10. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.
    Cancer Chemother Pharmacol, 58(6): 809-15. [Abstract] [Full-text]
11. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
    J Natl Cancer Inst, 98(17): 1238-47. [Abstract] [Full-text]
12. Randomized trial of an intervention to improve mammography utilization among a triracial rural population of women.
    J Natl Cancer Inst, 98(17): 1226-37. [Abstract] [Full-text]
13. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density.
    J Natl Cancer Inst, 98(17): 1215-26. [Abstract] [Full-text]
14. Prospective breast cancer risk prediction model for women undergoing screening mammography.
    J Natl Cancer Inst, 98(17): 1204-14. [Abstract] [Full-text]
15. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
    J Natl Cancer Inst, 98(17): 1183-92. [Abstract] [Full-text]
16. Expression of the hemochromatosis gene modulates the cytotoxicity of doxorubicin in breast cancer cells.
    Int J Cancer, 119(9): 2200-4. [Abstract] [Full-text]
17. Adult height, age at attained height, and incidence of breast cancer in premenopausal women.
    Int J Cancer, 119(9): 2231-5. [Abstract] [Full-text]
18. Role of birthweight in the etiology of breast cancer.
    Int J Cancer, 119(9): 2007-25. [Abstract] [Full-text]
19. Case-control study of risk factors for breast cancer in Nigerian women.
    Int J Cancer, 119(9): 2179-85. [Abstract] [Full-text]
20. Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women.
    Int J Cancer, 119(9): 2173-8. [Abstract] [Full-text]
21. Intrauterine environment and breast cancer risk in a population-based case-control study in Poland.
    Int J Cancer, 119(9): 2136-41. [Abstract] [Full-text]
22. PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer.
    Bioinformatics, 22(18): 2269-75. [Abstract] [Full-text]
23. Prediction of breast tumor progression by integrity of free circulating DNA in serum.
    J Clin Oncol, 24(26): 4270-6. [Abstract] [Full-text]
24. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
    J Clin Oncol, 24(26): 4245-53. [Abstract] [Full-text]
25. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer.
    J Clin Oncol, 24(26): 4262-9. [Abstract] [Full-text]
26. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer.
    J Clin Oncol, 24(26): 4254-61. [Abstract] [Full-text]
27. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
    J Clin Oncol, 24(26): 4236-44. [Abstract] [Full-text]
28. FNA of breast fibroadenoma: observer variability and review of cytomorphology with cytohistological correlation.
    Cytopathology, 17(5): 239-44. [Abstract] [Full-text]
29. Mastopathic fibroadenoma of the breast: a pitfall of aspiration cytology.
    Cytopathology, 17(5): 233-8. [Abstract] [Full-text]
30. Cytology is useful in breast screening: results and long-term follow-up of the Singapore Breast Screening Pilot Project.
    Cytopathology, 17(5): 227-32. [Abstract] [Full-text]
31. Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer. An immunocytochemical study.
    J Steroid Biochem Mol Biol, 101(2): 136-44. [Abstract] [Full-text]
32. Induction of E-cadherin endocytosis by loss of protein phosphatase 2A expression in human breast cancers.
    Biochem Biophys Res Commun, 349(1): 255-60. [Abstract] [Full-text]
33. PTP-PEST phosphatase variations in human cancer.
    Cancer Genet Cytogenet, 170(1): 48-53. [Abstract] [Full-text]
34. Consistency in seroma contouring for partial breast radiotherapy: impact of guidelines.
    Int J Radiat Oncol Biol Phys, 66(2): 372-6. [Abstract] [Full-text]
35. The impact of lobular carcinoma in situ in association with invasive breast cancer on the rate of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy.
    Int J Radiat Oncol Biol Phys, 66(2): 365-71. [Abstract] [Full-text]
36. Long-term toxicity of an intraoperative radiotherapy boost using low energy X-rays during breast-conserving surgery.
    Int J Radiat Oncol Biol Phys, 66(2): 377-81. [Abstract] [Full-text]
37. Low local recurrence rate without postmastectomy radiation in node-negative breast cancer patients with tumors 5 cm and larger.
    Int J Radiat Oncol Biol Phys, 66(2): 358-64. [Abstract] [Full-text]
38. Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score.
    Int J Radiat Oncol Biol Phys, 66(2): 352-7. [Abstract] [Full-text]
39. Poly(gamma,L-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice.
    Biomaterials, 27(35): 5958-65. [Abstract] [Full-text]
40. High-resolution analysis of chromosome rearrangements on 8p in breast, colon and pancreatic cancer reveals a complex pattern of loss, gain and translocation.
    Oncogene, 25(41): 5693-706. [Abstract] [Full-text]
41. Intraoperative touch imprint cytological analysis of sentinel lymph nodes for the presence of metastases in breast cancer.
    Onkologie, 29(8): 372-5. [Abstract] [Full-text]
42. Tumour-positive sentinel node findings in patients with ductal carcinoma in situ.
    J Surg Oncol, 94(5): 380-4. [Abstract] [Full-text]
43. Ipsilateral breast tumor reappearance in patients treated with conservative surgery after primary chemotherapy. The role of surgical margins on outcome.
    J Surg Oncol, 94(5): 375-9. [Abstract] [Full-text]
44. Primary angiosarcoma of the breast: observations in Asian Indian women.
    J Surg Oncol, 94(5): 368-74. [Abstract] [Full-text]
45. Ductal carcinoma in situ: value of sentinel lymph node biopsy.
    J Surg Oncol, 94(5): 426-30. [Abstract] [Full-text]
46. Added value of ultrasound in screening the clinically negative axilla in breast cancer.
    J Surg Oncol, 94(5): 364-7. [Abstract] [Full-text]
47. Normalized data for the estimation of fetal radiation dose from radiotherapy of the breast.
    Br J Radiol, 79(946): 818-27. [Abstract] [Full-text]
48. Breast radiotherapy in women with pectus excavatum (funnel chest): is the lateral decubitus technique an answer? A dosimetric study.
    Br J Radiol, 79(946): 785-90. [Abstract] [Full-text]
49. Dosimetric and treatment planning considerations for radiotherapy of the chest wall.
    Br J Radiol, 79(946): 828-36. [Abstract] [Full-text]
50. Ultrasound spectrum in intraductal papillary neoplasms of breast.
    Br J Radiol, 79(946): 843-9. [Abstract] [Full-text]
51. MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation.
    Mol Cell Biol, 26(19): 7269-82. [Abstract] [Full-text]
52. DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth.
    Mol Cell Biol, 26(19): 7116-29. [Abstract] [Full-text]
53. Identification of BRCA1 and BRCA2 mutations from Korean breast cancer patients using denaturing HPLC.
    Biochem Biophys Res Commun, 349(2): 604-10. [Abstract] [Full-text]
54. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells.
    Endocrinology, 147(10): 4831-42. [Abstract] [Full-text]
55. Breast cancer treatment of older women in integrated health care settings.
    J Clin Oncol, 24(27): 4377-83. [Abstract] [Full-text]
56. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
    J Clin Oncol, 24(27): 4384-90. [Abstract] [Full-text]
57. Allometric scaling law questions the traditional mechanical model for axillary lymph node involvement in breast cancer.
    J Clin Oncol, 24(27): 4391-6. [Abstract] [Full-text]
58. Four primary malignancies successively occurred in a BRCA2 mutation carrier: a case report.
    Cancer Invest, 24(6): 611-4. [Abstract] [Full-text]
59. Cyclin e expression and prognosis in breast cancer patients: a meta-analysis of published studies.
    Cancer Invest, 24(6): 581-7. [Abstract] [Full-text]
60. Outcomes of women with metachronous breast and ovarian carcinomas.
    Gynecol Oncol, 103(1): 190-4. [Abstract] [Full-text]
61. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344).
    J Natl Cancer Inst, 98(18): 1335-8. [Abstract] [Full-text]
62. Effectiveness of radiation therapy in older women with ductal carcinoma in situ.
    J Natl Cancer Inst, 98(18): 1302-10. [Abstract] [Full-text]
63. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    J Natl Cancer Inst, 98(18): 1285-91. [Abstract] [Full-text]
64. Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings.
    J Natl Cancer Inst, 98(18): 1275-84. [Abstract] [Full-text]
65. Lobular neoplasia at 11-gauge vacuum-assisted stereotactic biopsy: correlation with surgical excisional biopsy and mammographic follow-up.
    AJR Am J Roentgenol, 187(4): 949-54. [Abstract] [Full-text]
66. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
    Cancer, 107(6): 1348-54. [Abstract] [Full-text]
67. The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health Study.
    Cancer, 107(6): 1240-7. [Abstract] [Full-text]
68. Significance of micrometastases on the survival of women with T1 breast cancer.
    Cancer, 107(6): 1234-9. [Abstract] [Full-text]
69. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero.
    Cancer, 107(6): 1219-26. [Abstract] [Full-text]
70. Excellent survival, cancer type, and Nottingham grade after atypical lobular hyperplasia on initial breast biopsy.
    Cancer, 107(6): 1227-33. [Abstract] [Full-text]
71. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy.
    Cancer, 107(6): 1248-54. [Abstract] [Full-text]
72. A bidirectional "alpha(v)beta(3) integrin-ERK1/ERK2 MAPK" connection regulates the proliferation of breast cancer cells.
    Mol Carcinog, 45(10): 795-804. [Abstract] [Full-text]
73. Familial relative risk estimates for use in epidemiologic analyses.
    Am J Epidemiol, 164(7): 697-705. [Abstract] [Full-text]
74. Improving the concordance of mammography assessment and management recommendations.
    Radiology, 241(1): 67-75. [Abstract] [Full-text]
75. Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells.
    Biochem Biophys Res Commun, 349(3): 1117-24. [Abstract] [Full-text]
76. Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma.
    Hum Pathol, 37(10): 1316-23. [Abstract] [Full-text]
77. Multilectin affinity chromatography for characterization of multiple glycoprotein biomarker candidates in serum from breast cancer patients.
    Clin Chem, 52(10): 1897-905. [Abstract] [Full-text]
78. Evaluation of ERBB2 gene status and chromosome 17 anomalies in male breast cancer.
    Am J Surg Pathol, 30(10): 1292-8. [Abstract] [Full-text]
79. The associations between severity of early postoperative pain, chronic postsurgical pain and plasma concentration of stable nitric oxide products after breast surgery.
    Anesth Analg, 103(4): 995-1000. [Abstract] [Full-text]
80. Ovarian cyst torsion and extreme ovarian stimulation in a premenopausal patient treated with tamoxifen for ductal carcinoma in situ of the breast.
    Am J Obstet Gynecol, 195(4): e5-6. [Abstract] [Full-text]
81. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
    BMC Cancer, 6: 225. [Abstract] [Full-text]
82. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
    Oncogene, 25(44): 6003-14. [Abstract] [Full-text]
83. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.
    J Clin Oncol, 24(28): 4611-9. [Abstract] [Full-text]
84. Magnetic resonance imaging captures the biology of ductal carcinoma in situ.
    J Clin Oncol, 24(28): 4603-10. [Abstract] [Full-text]
85. Genomic prediction of locoregional recurrence after mastectomy in breast cancer.
    J Clin Oncol, 24(28): 4594-602. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.